Equities

AREV Life Sciences Global Corp

AREVF:PKC

AREV Life Sciences Global Corp

Actions
  • Price (USD)0.01
  • Today's Change0.00 / 0.00%
  • Shares traded100.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Apr 17 2024 15:41 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

AREV Life Sciences Global Corp. is a Canada-based fully integrated, early-stage life science discovery company. The Company produces ingredients and formulates therapeutic interventions with plans to deliver innovation in clinical nutrition, supplements, topicals and rational drug design, based on science. Its business model leverages its core competency of extraction to produce ingredients and compounds for its pipeline of products. The Company’s nutraceutical product formulations seek to be sold under its BARE and Wright and Well brands or produced for third parties on a licensed white label basis. Its BARE and Wright and Well Brands of finished products include natural health products, including cannabidiol (CBD)-infused products such as Canna-Mulsion and NaturVax, an anti- viral supplement; NaturRelax, a natural Sleep Aid; Natur Relief, an anti- inflator and pain relief product, and a line of CBD skincare products and medicinal oils and edibles.

  • Revenue in CAD (TTM)7.21k
  • Net income in CAD-239.55k
  • Incorporated2016
  • Employees0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.